Skip to main content

Table 2 Distribution of identified pneumococcal isolates. Two years (2007/2008) prior to PCV were compared to 3 years after (2011–2013). Of the total S. pneumoniae included in the present study, 78.8 % (n = 1234) were available for serotyping prior to and 79.2 % (n = 1352) after PCV introduction. p-values were calculated for relative incidences. Non-PHiD-CV10 serotypes that represent less than 2.5 % of serotypes before and after PCV introduction are grouped as “Others”

From: Reduction of Streptococcus pneumoniae in upper respiratory tract cultures and a decreased incidence of related acute otitis media following introduction of childhood pneumococcal conjugate vaccines in a Swedish county

Serotype/Serogroup Prior to PCV (2007/2008)
% (n)
After PCV (2011–2013)
% (n)
P-value
1 0.0 (1) 0.0 (0) NA
4 1.8 (22) 0.4 (5) <0.001
5 0.0 (1) 0.0 (0) NA
6B 11.1 (137) 1.6 (21) <0.001
7F 1.5 (19) 0.9 (12) 0.149
9V 1.6 (20) 0.7 (10) 0.043
14 6.4 (79) 1.8 (25) <0.001
18C 2.2 (26) 1.3 (17) 0.093
19F 11.5 (141) 3.1 (42) <0.001
23F 9.1 (112) 2.0 (28) <0.001
Total PHiD-CV10 serotypes 45.2 (558) 11.8 (160) <0.001
3 7.0 (86) 8.8 (119) 0.450
6A 9.1 (112) 3.3 (44) <0.001
6C 2.9 (36) 6.7(91) <0.001
10 0.7 (8) 2.9 (38) <0.001
11A 4.0 (49) 10.0 (135) <0.001
15B 2.1 (26) 9.3 (124) <0.001
19A 3.7 (46) 9.9 (134) <0.001
23A 3.0 (38) 6.4 (87) <0.001
23B 0.3 (4) 4.2 (57) <0.001
35 2.6 (32) 7.4 (100) <0.001
Othersa 13.8 (170) 10.9 (148) 0.111
Total non-PHiD-CV10 serotypes 49.2 (607) 79.7 (1077) <0.001
Non-typeable 5.6 (69) 8.6 (116) <0.001
  1. aOthers were in ascending order: 2, 6D, 7C, 8, 9A, 9N, 11B, 11C, 12, 13, 15A, 15C, 16, 17, 18A, 18B, 18F, 20, 21, 24F, 28, 31, 24, 33, 37, 38, 39, 40, and 42
\